FSD Pharma
Clinical-stage biopharmaceutical company developing small-molecule therapies for neurological and inflammatory disorders and consumer/hospital oral liquid formulations for alcohol recovery. Operates a development pipeline built around a patented small-molecule new chemical entity with preclinical efficacy in remyelination models and completed Phase I human dosing. Maintains regulatory advisors, investor relations function, and a multidisciplinary scientific leadership team.
Industries
Nr. of Employees
small (1-50)
FSD Pharma
55 University Ave., Suite 1003, Toronto, ON, M5J 2H7, Canada
Products
Patented small-molecule candidate for demyelinating disease
Patented small-molecule neuroprotective compound series developed to prevent and reverse myelin degradation; demonstrated preclinical efficacy in remyelination and functional recovery and advanced to Phase I human safety studies.
Oral liquid formulation for alcohol recovery (consumer and hospital applications)
Oral liquid formulation intended to accelerate ethanol metabolism and restore mental alertness after alcohol consumption; described for both consumer use and emergency department/hospital support and planned for clinical validation.
Patented small-molecule candidate for demyelinating disease
Patented small-molecule neuroprotective compound series developed to prevent and reverse myelin degradation; demonstrated preclinical efficacy in remyelination and functional recovery and advanced to Phase I human safety studies.
Oral liquid formulation for alcohol recovery (consumer and hospital applications)
Oral liquid formulation intended to accelerate ethanol metabolism and restore mental alertness after alcohol consumption; described for both consumer use and emergency department/hospital support and planned for clinical validation.
Expertise Areas
- Clinical trial management
- Neurodegenerative drug development
- Small-molecule medicinal chemistry and NCE development
- Preclinical animal models and efficacy testing
Key Technologies
- Small-molecule discovery and medicinal chemistry
- Oral formulation development (solid and liquid)
- Rapid-absorption oral liquid formulations
- Preclinical disease models
News & Updates
Company filed and posted links to a U.S. federal complaint and amended complaint alleging possible stock price manipulation by financial institutions seeking damages in excess of $700,000,000 USD.
Presentation and webcast participation at the Sidoti Micro Cap Conference.
Press release summarizing the company's mission and clinical development efforts for multiple sclerosis.
Press release highlighting preclinical advances for the company's demyelination program.
Video and press content describing support for responsible drinking and the company's oral formulation for alcohol recovery.
Informational video about the demyelination program and preclinical/clinical status.
Company filed and posted links to a U.S. federal complaint and amended complaint alleging possible stock price manipulation by financial institutions seeking damages in excess of $700,000,000 USD.
Presentation and webcast participation at the Sidoti Micro Cap Conference.
Press release summarizing the company's mission and clinical development efforts for multiple sclerosis.
Press release highlighting preclinical advances for the company's demyelination program.
Video and press content describing support for responsible drinking and the company's oral formulation for alcohol recovery.
Informational video about the demyelination program and preclinical/clinical status.